Zhejiang Taimei Expands Investment Partnership With Government-Backed Fund

Zhejiang Taimei Medical Technology Co Ltd Class H ( (HK:2576) ) has issued an update.

Zhejiang Taimei Medical Technology has amended the terms of an investment partnership to bring in Jiaxing Yangtze River Delta Angel Venture Capital Partnership as a new limited partner, raising the vehicle’s total committed capital from RMB227.27 million to RMB329.50 million. The general partner Kaifeng Taimei will also lift its own contribution, partly funded indirectly by the group, while existing capital commitments from Taimei and other limited partners remain unchanged.

The higher capital base is expected to allow the partnership to back more projects and increase the average ticket size of each investment, although no specific targets have yet been identified. The new investor is a government-led industrial fund from Jiaxing, Zhejiang, which is ultimately owned by a local public institution and is independent from Zhejiang Taimei, potentially strengthening the partnership’s access to government-backed capital and regional industrial resources.

The most recent analyst rating on (HK:2576) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Zhejiang Taimei Medical Technology Co Ltd Class H stock, see the HK:2576 Stock Forecast page.

More about Zhejiang Taimei Medical Technology Co Ltd Class H

Zhejiang Taimei Medical Technology Co., Ltd. is a PRC-incorporated medical technology company listed in Hong Kong. The group participates in industry-focused investment through partnerships, alongside affiliates such as Taimei Intelligence and Kaifeng Taimei, to support long-term projects in healthcare-related and regional development sectors.

Average Trading Volume: 50,327

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$2.72B

For a thorough assessment of 2576 stock, go to TipRanks’ Stock Analysis page.